Edmond DE Rothschild Holding S.A. Takes Position in Caris Life Sciences, Inc. $CAI

Edmond DE Rothschild Holding S.A. acquired a new position in Caris Life Sciences, Inc. (NASDAQ:CAI) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 27,965 shares of the company’s stock, valued at approximately $498,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. bought a new position in Caris Life Sciences in the fourth quarter worth about $370,000. TD Waterhouse Canada Inc. purchased a new position in shares of Caris Life Sciences during the 4th quarter worth approximately $2,498,000. DekaBank Deutsche Girozentrale purchased a new position in shares of Caris Life Sciences during the 4th quarter worth approximately $3,942,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Caris Life Sciences in the 4th quarter worth approximately $1,240,000. Finally, Courier Capital LLC purchased a new position in shares of Caris Life Sciences in the 4th quarter valued at approximately $231,000.

Analyst Ratings Changes

Several research firms recently weighed in on CAI. Wolfe Research lowered Caris Life Sciences from an “outperform” rating to a “peer perform” rating in a research report on Monday, June 1st. Evercore reissued an “outperform” rating and set a $26.00 price objective on shares of Caris Life Sciences in a research report on Thursday, August 6th. New Street Research began coverage on shares of Caris Life Sciences in a report on Friday, May 8th. They set a “market perform” rating on the stock. BTIG Research upped their target price on shares of Caris Life Sciences from $32.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Caris Life Sciences in a research note on Friday, August 7th. Seven investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Caris Life Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.33.

Caris Life Sciences Stock Performance

Caris Life Sciences stock opened at $24.58 on Friday. Caris Life Sciences, Inc. has a twelve month low of $14.19 and a twelve month high of $42.50. The company has a quick ratio of 4.88, a current ratio of 5.53 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $6.95 billion, a P/E ratio of 68.28 and a beta of 0.68. The stock’s 50 day moving average is $18.27 and its 200 day moving average is $18.52.

Caris Life Sciences announced that its board has approved a share buyback plan on Monday, June 8th that permits the company to buyback $100.00 million in outstanding shares. This buyback authorization permits the company to reacquire up to 2.1% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s leadership believes its stock is undervalued.

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.